Jubilant Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.jubilanttx.com
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Locally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2022-03-07
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Jubilant Therapeutics Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT05268666
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
🇺🇸NEXT Virginia, LLC, Fairfax, Virginia, United States
© Copyright 2025. All Rights Reserved by MedPath